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Urinary incontinence (Ul) is the involuntary leakage of urine, while
ou"r"*iu" bladder (OABi is characterised by frequency, nocturia and
urgency, with or without incontinence.This paper provides guidelines for
the management of Ul and OAB, focusing on primary health care'
Although Ul and oAB negatively impact on the patient's quality of life
more severely than diabetes mellitus or rheumatoid arthritis, surveys
have shown that more than 60% of persons with Ul never mention their
problem to a doctor or nurse.Therefore, the primary care setting is ideal
for screening, basic evaluation, and initial management of Ul and OAB.
A focused history and examination will usually enable the practitioner to
distinguish between the different types of incontinence, such as stress,
urge (overactive bladder), mixed, overflow and continuous incontinence. lt
should include a vaginal examination and cough test in women, rectal
examination in men, dipsticks urinalysis, and assessment of the post-void
residual urine.A bladder diary filled in by the patient can be very useful.
There may be reversible conditions causing or contributing to the
patient's incontinenCe. such as urinary tract infection. ln certain cases
referral to a specialist is required, e.g. patients with incontinence after
previous surgery, or associated with pain or hematuria.
However, many patients with symPtoms of OAB or Ul can be eff
ectively treated at the primary care level. Management options include
lifesryle modification (e.g. smoking cessation and weight loss), pelvic floor
exercises, and pharmacotherapy. Overactive bladder can be treated with
muscarinic antogonists such as tolterodine and orybutinin.
S A Fom Praa 2002,25(2): 4-10
.. l .M BaCkgfOUpglrcwi
Urinary incontinence (Ul) is the
unwanted and involuntary leakage of
urine, while overactive bladder (OAB)
is associated with urinary frequency,
nocturia and urgency, with or without
urge incontinence (Table l). Both are
significant health problems, particular-
ly for elderly women.
Table l.' Symtoms of
Overactive Bladder





While the exact incidence is not
known in South Africa, studies else-
where suggest the magnitude of the
problem is much greater than is
apparent. ln the USA the prevalence
of  Ul  is  about  3 l% in women
between 42 and 50 years old, and
38% in community dwell ing women
and men who are older than 60.' The
prevalence of OAB is 30% to 40% in
persons over 75 years of age.'Thus, it
is more common in the elderly than
diabetes, and similar in prevalence to
asthma. However, Ul and OAB are
not inevitable consequences of aging,
and many cases can be cured or man-
aged using a combination of currently
available treatments.'
In July 200 | a committee consisting of
urologists, gynaecologists, primary
care physicians and pharmacologists
convened to recommend guidelines
for the treatment of Ul and OAB.The
committee followed the principles of
evidence-based medicine used in the
process of making clinical decisions a.
The strongest weight was given
to data from systematic reviews,
meta-analyses and published findings
of randomised controlled trials.
Where such data were not available,
the committee followed the approach
taken by the Agency for Health Care
Policy and Research, which combines
a detailed, evidence-based approach
with a process that accommodates
expert opinion.s
Our guidelines focus on current
treatments for Ul and OAB that can
be used in general practice.\rye want
to emphasize that these recommen-
dations are not rigid mandates, and
that the final decision concerning the
therapeutic regimen for an individual
patient rests with the treating physi-
cian.
The lmpact of Incontinence
Surveys have shown that more than
60% of Dersons with Ul never men-
tion their problem to a doctor or
nurse.' ln both men and women OAB
negatively impacts on quality of life
more severely than diabetes mellitus
or rheumatoid arthrit is. '/ In 1995 the
direct cost of caring for incontinent
persons over the age of 65 was esti-
mated to be $28 bil l ion annually in
the USA, which is greater than the
combined Medicare costs for open-
heart surgery and end-stage renal dis-
ease.'
ldentification of Patients at Risk
The primary care setting is ideal for
screening, basic evaluation, and init ial
management of Ul and OAB. Prior to
implementation of any intervention, it
is important to understand the
underlying causes of the various types
of Ul and OAB (Table l l).
Documented risk factors that are
associated with Ul and OAB are list-
ed below.
l. Age. Pelvic muscle relaxation in
women accelerates rapidly after
menoPause.
2. Pregnancy and childbirth. Ul is
related to risk factors such as for-
Table l l: Types of Urinary Incontinence
Type of lncontinence Underlying Cause Associated Symptoms
Stress Sphincter dysfunction due to weakness
of the pelvic f loor muscles.
Urine leakage occurs with increased




Involuntary and uninhibited detrusor
contractions, due to detrusor instabi l i ty.
Sudden urge to pass urine, inabi l i ty to
delay voiding, often associated with frequency
and nocturia
Mixed A combination of bladder and urethral
dysfunction causing stress and urge
incontinence.
Combination of above symptoms.
Overflow An acontractile detrusor (e.g. diabetic
neuropathy) or bladder outflow obstruction
(e.g. prostatic enlargement).




Vesico-vaginal fistula or sphincter damage
(e.g. after prostatectomy)
Constant leakage of urine, no urge to void,
because bladder never fihs
4.
5.
ceps delivery, episiotomy, third
degree tears and pudendal anes-
thesia.t
Depletion of estrogens. Oestrogen
depletion is associated with dimin-
ished urethral mucosal vascularity
and thickness, reducing its abil ity
to maintain a tight seal.
Pelvic and prostate surgery. There
is an increased risk of Ul after hys-
terectomy and prostatectomy.'o
Smoking. Nicotine may have a




Obesity. Weight gain and morbid
obesity may increase the suscepti-
bil i ty for Ul. ' '
High-impact physical activit ies.
Approximately one third of
women experience urine loss dur-
ing strenuous physical activity.rl
Medication. Diuretics may exacer-
bate symptoms of OAB; anti-
cholinergics (e.g. antidepressants)
may cause urinary retention with
overflow Ul; sedatives, hypnotics
and narcotic analgesics may cause
urinary retention, sedation, and
delirium, which can all lead to Ul
episodes.
9. Chronic diseases. Multiple sclero-
sis, spinal cord injury, diabetes
mellitus, Parkinson's disease and
stroke may cause bladder neu-




Very often the patient can be easily
classified as having (l) reversible con-
ditions leading to Ul, (2) complicated
or (3) uncomplicated Ul.
(/) Reversible conditions
The mnemonic DIAPPERS is a useful
aid in excluding reversible condi-
tions.ra Delirium needs to be treated
before too much attention is paid to
the investigation of Ul. Infection
of the urinary tract should be
treated according to urine culture
and sensitivity. Atrophic vaginit is is
not necessarily a cause of inconti-
nence, but may require treatment in
its own right. Pharmaceuticals uch
as cr-blockers, diuretics, tricyclic anti-
depressants or anticholinergics influ-
ence bladder function. Psychological
problems such as anxiety may cause
symptoms of OAB. Excessive fluid or
caffeine intake may cause diuresis and
contribute to Ul. A urinary diary
(bladder diary) is very useful to assess
fluid intake and urine volume.
Restricted mobility may lead to
incontinence if the patient cannot get
to the toilet in time. Stool diff iculty
(constipation) may be associated with
retention and overflow incontinence.
(2) Complicoted incontinence
Recurrent or persistent incontinence
after previous treatment, pain associ-
ated with incontinence, retention or
diff icult voiding, macroscopic hema-
turia, recurrent urinary tract infection
(UTl) or previous radical pelvic sur-
gery or radiation are conditions that
require referral. ln patients with total
incontinence after complicated child-
birth a fistula is suspected.The patient
with underlying neurological condi-
tions such as Parkinson's disease or
multiple sclerosis is also best
referred.
(3) Uncomplicoted incontinence
The patient with Ul alone must be
questioned for stress incontinence at
the moment of cough, sneeze or
physical activity, or urge incontinence,
or a combination of the two.
Examination
A general clinical examination should
always be done. Further examination
is focused on the cause and severity
of the incontinence. The patient is
best evaluated with a comfortable full
bladder. The abdomen is palpated for
a bladder and, if distended, it must be
checked after voiding.
Neurologic examination should as-
sess the lower extremities for normal
sensation, strength and deep tendon
reflexes. Stimulation of the perianal
skin (S2-4) normally elicits the anal
wink (visible contraction of the anal
sphincter).
Pelvic examination entails inspection
of the vulva and vagina for signs of
oestrogen deficiency, skin irritation or
infection. Prolapse is best evaluated
by vaginal examination using a Simm's
speculum. The three compartments
are individually assessed, namely ante-
rior (cystocele), vaginal vault or
uterus (enterocele, uterovaginal pro-
lapse) and posterior (rectocele). A
vesico-vaginal fistula may be diag-
nosed with a speculum or with
bimanual vaginal examination.
The cough test can be done with the
patient in the supine position, giving a
few vigorous coughs. lf it is negative, it
should be repeated standing (Table
il r).







In men, a genital examination is per-
formed to detect abnormalities of the
foreskin, glans, urethral meatus and
perineal skin. In men and women, a
digital rectal examination (DRE) is
performed to assess for stool
impaction, rectal sphincter tone, and
sensation. Assessment of the orostate
in men is essential.
Urinalysis and Post-void Residual. The
patient voids and the urine volume is
measured. Urine dipstix is done and, if
abnormal, urine is sent for MC&S
(Table lV). Thereafter, the post-void
residual (PVR) is determined (Table
V). Examiners with adequate experi-
ence can pass an F | 8 catheter in men
to exclude a urethral stricture.A PVR
of 100 mL or less may be considered
normal .
Ioble lV: Urinalysis
.  Fresh, clean-catch, mid-stream
. Dipstick test for:
- Blood
- Leucocytes
- Nitr i tes
- Glucose
- Protein
Toble V: Post-void Residual
Urine (PVR)
.  Abdominal palpation (may be
inaccurate)
. Accurate measurement by:
- Ultrasound
- Catheterization (caution in
men)
Bladder Diary
This is an extremely valuable tool in
the management of Ul and OAB.The
patient is asked to fi l l  in a 3-day blad-
der diary and return for a consulta-
tion where treatment is discussed.
The urinary diary can assess fluid
intake, urine volume, the number and
time interval between voids per day,
incontinence episodes, number of






The GP can direct the behavioral
treatment oPtions specific to the
patient's diagnosis of stress, urge, or
mixed Ul  and OAB (TableVl) . l f  mot i -
vated, most people treated with
behavioral techniques show improve-
ment ranging from complete dryness
to decreased incontinence episodes.'
Counsel ing on Flu id Intake
Dehydration can potentiate constipa-
tion, concentrate the urine, and
increase the irritative effects of
dietary substances. The recommend-
ed daily intake is 1500 ml. Some
patients may use excessive fluid
intake to prevent acidic urine from
causing urinary urgency and frequen-
cy, but this may contribute to Ul.
Some patients only complain of noc-
turnal enuresis and/or nocturia, with-
out daytime incontinence or frequen-
cy.With aging, urine output increases
during rest in the supine position. A
bladder diary can help determine if
the patient is experiencing reverse
diures is .
Pelvic floor muscle rehabil itation
For pelvic floor physiotherapy and
bladder retraining the GP should
refer patients to a physiotherapist or
other health professional with spe-
c ia l is t  t ra in ing in  these techniques.
Pelvic floor muscle rehabil itation
involves oelvic muscle exercises
(PME), known commonly as "Kegel"
exercises.'s PME are most effective in
stress incontinence. An average of
76% improvement in Ul after 4 to 6
weeks of intensive daily PME has been
reported.' '  Weighted vaginal cones
provide proprioceptive biofeedback,
providing the woman with the
sensation to contract her pelvic floor
muscles, and can be used alone or in
conjunction with PME.r Biofeedback
therapy assists the patient in identify-
ing the pelvic floor muscles.
Toble Vl.' Lifestyle Modification
Adequate Fluid
lntal<e
Patients with a high fluid intake (> 2400 ml/day) should
lower their intake, while those with a low f luid intake
(< 1500 ml/day) may benefit from an increased intake,
but i t  should be stopped after 6 p.m.
Smoking
Cessation
Nicotine is irr i tat ing to the detrusor, and chronic
coughing may cause Ul.
Dietary
Modif icat ion
Elimination of one or al l  of the i tems below may improve
bladder control:
. Caffeine: coffee (even decaffeinated), tea, cola
DeveraSes
. Alcoholic drinks
. Citrus juice and fruit






Weight reduction Weight reduction is associated with improvements in
urinary symptoms
Bowel Regularity Increased f iber, exercise, and f luid can prevent
constipation and straining at bowel movements leading
to Ul.
Adopted from Newman DK The Urinary Incantinence Sourcebook, 2nd ed, Colifornia,
Lowell House, 1999.
Electromyogram (EMG) probes (vagi-
nal or rectal) are used to display
pelvic floor muscle activity on a
patient-viewing monitor. PME with
biofeedback therapy have shown
improvement in incontinence that
ranges from 80% to 85%.r'17
Bladder retraining and urge
strategy
Bladder retraining involves a strict
schedule of voluntary voiding "on the
clock". These intervals are increased
progressively to increase functional
bladder capacity. Urge strategy focus-
es on the cortical abil ity to delay
voiding by using strategies such as
concentration on a task, slow deep
breathing, or rapid intense pelvic
muscle contractions. r8
.rM Pharmacotherap| 8,,
a) Overactive bladder (OAB) [detru-
sor instabil ity (Dl)] responds to
drugs reducing bladder contractili-
ty: Anticholinergic agents, e.g. oxy-
butynin and tolterodine, act at
postganglionic parasympathetic
cholinergic receptor sites on the
detrusor, reducing the strength of
contractions. Tricyclic antidepres-
sants, e.g. imipramine, have
anticholinergic effects, block
presynaptic uptake of amine
neurotransmitters and directly
inhibit detrusor muscle. Alpha-
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muscarinic antagonists which are
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A progressive rural New Zealand practice is seeking to employ a salaried General Practitioner at
its clinic situated in the Central North Island town of Taumarunui.
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No financial or business risk to the GP
Minimal p;rerwork - the practice manager
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Clinical support from our C-eneral ttactice
Management Group
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A sensible after-hours roster
A satisfoing, rewarding work environment
Support for continuing meclical education
incl ud i ng continuing meclical eclucation leave
Annual leave
The opportuni$ for well paicl after hours work
at Taumarunui Hospital
A caring, supportive communigl
A high quality lifesgle
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